Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03777410 · ClinicalTrials.gov registry record
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
A clinical trial, sponsored by Travera.
- Terminated
- Registry status
- 33
- Enrollment target
NCT03777410 is a clinical trial that was terminated before completion, run by Travera. The registered enrollment target is 33 participants.
The verdict
NCT03777410 was terminated before completion, sponsored by Travera.
- TERMINATED
- Registry status
- 33 participants
- Enrollment target
Study Summary
This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regimen. The primary study objective is to explore whether the single-cell MAR biomarker can predict patient response in RRMM patients. In order to enable this primary objective, two patient cohorts will be required. First, a small vanguard cohort of patients with treatment naïve disease to define drug concentrations used for testing, and second, the main RRMM patient cohort. Data will be collected to estimate the biomarker's predictive properties (accuracy, sensitivity, specificity), and to support improvement of the MAR biomarker through additional research and discovery within the study dataset.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2024-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03777410
The ClinicalTrials.gov registry entry for NCT03777410 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Travera, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03777410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03777410 about?
NCT03777410 is a clinical study titled "Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma". This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regim...
What is the current status of trial NCT03777410?
This trial is currently terminated. The enrollment target is 33 participants. The study started on 2019-02-11. Estimated completion is 2024-06-30.
Who is sponsoring clinical trial NCT03777410?
This trial is sponsored by Travera, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.